@article{dcb356a530014e74a02a497641ddc518,
title = "Viral hepatitis in haemophilia: historical perspective and current management",
abstract = "The introduction of clotting factor concentrates has substantially improved the lives of people with clotting factor deficiencies. Unfortunately, the transmission of blood-borne viral infections through these plasma-derived products led to a huge epidemic of human immunodeficiency virus and viral hepatitis in people with haemophilia (PWH). In a significant proportion of PWH exposed to these viruses, the ensuing decades-long chronic infection resulted in excess morbidity and mortality. Fortunately, developments in the safety of blood products, as well as vaccination and highly effective antiviral treatments have improved the prospects of PWH. The present article reviews the background of the viral hepatitis epidemic in PWH, the natural history of hepatitis B and C infections and their long-term management.",
keywords = "HBV, HCV, HIV, haemophilia, hepatitis C",
author = "Isfordink, {Cas J.} and {van Erpecum}, {Karel J.} and {van der Valk}, Marc and Mauser-Bunschoten, {Evelien P.} and Michael Makris",
note = "Funding Information: Cas J. Isfordink has received research funding from Gilead. Karel J. van Erpecum has participated in Advisory Boards of Gilead, Abbvie, Janssen and MSD and consultancy for Abbvie (no personal benefit, all fees to UMC Utrecht) and participates in the Celine (hepatitis C Elimination In the Netherlands) project (a multicentre initiative to eradicate hepatitis C from the Netherlands: sponsored by Gilead). Marc van der Valk has received consultancy fees through his institution from Abbvie, Janssen, MSD, ViiV, Gilead and unrestricted research support from Abbvie, Janssen, MSD, Gilead. Michael Makris has provided consultancy to Grifols, Sanofi, NovoNordisk and CSL Behring. He is also the project lead for the (European Haemophilia Safety Surveillance (EUHASS) project that receives support from Bayer, BPL, CSL Behring, Kedrion, NovoNordisk, Octapharma, Pfizer, Roche, Sobi and Takeda. Evelien P. Mauser‐Bunschoten has no conflict of interests. Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd",
year = "2021",
month = oct,
doi = "https://doi.org/10.1111/bjh.17438",
language = "English",
volume = "195",
pages = "174--185",
journal = "British journal of haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",
}